Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.

about

Recent Advances in Prostate Cancer Treatment and Drug Discovery.Heterocyclic sterol probes for live monitoring of sterol trafficking and lysosomal storage disorders

P2860

Q54111821-04E00806-97C6-4B0B-9931-C66787B3FD52 Q58695608-B4B8857D-9859-4ECB-8DF7-C4331C3881C3

P2860

Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.

Item

http://www.wikidata.org/entity/Q38618888

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.

@en

type

Item

label

Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.

@en

prefLabel

Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.

@en

P1476

Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.

@en

P2860

Abiraterone in metastatic prostate cancer without previous chemotherapy

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Abiraterone and increased survival in metastatic prostate cancer

Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomis

Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data

Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born.

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer

P2888

s40265-017-0799-9

P31

scholarly article

P356

10.1007/S40265-017-0799-9

http://www.w3.org/2001/XMLSchema#string

P50

Lesley J Scott

P577

2017-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091233224

http://www.w3.org/2001/XMLSchema#string

P698

28819727

http://www.w3.org/2001/XMLSchema#string

Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.

about

P2860

P2860

Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2860

P2888

P31

P356

P50

P577

P6179

P698

P356

P1433

P1476

P2860

P2888

P31

P356

P50

P577

P6179

P698